- Home
- ANNX vs CATX Comparison
ANNX vs CATX Comparison
Compare ANNX & CATX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANNX
- CATX
- Stock Information
- Founded
- ANNX 2011
- CATX 1983
- Country
- ANNX United States
- CATX United States
- Employees
- ANNX N/A
- CATX N/A
- Industry
- ANNX Biotechnology: Pharmaceutical Preparations
- CATX Medical/Dental Instruments
- Sector
- ANNX Health Care
- CATX Health Care
- Exchange
- ANNX Nasdaq
- CATX Nasdaq
- Market Cap
- ANNX 253.8M
- CATX 239.0M
- IPO Year
- ANNX 2020
- CATX N/A
- Fundamental
- Price
- ANNX $2.64
- CATX $3.31
- Analyst Decision
- ANNX Strong Buy
- CATX Strong Buy
- Analyst Count
- ANNX 5
- CATX 11
- Target Price
- ANNX $13.00
- CATX $12.90
- AVG Volume (30 Days)
- ANNX 1.6M
- CATX 641.6K
- Earning Date
- ANNX 11-13-2025
- CATX 11-11-2025
- Dividend Yield
- ANNX N/A
- CATX N/A
- EPS Growth
- ANNX N/A
- CATX N/A
- EPS
- ANNX N/A
- CATX N/A
- Revenue
- ANNX N/A
- CATX $1,235,000.00
- Revenue This Year
- ANNX N/A
- CATX N/A
- Revenue Next Year
- ANNX N/A
- CATX N/A
- P/E Ratio
- ANNX N/A
- CATX N/A
- Revenue Growth
- ANNX N/A
- CATX N/A
- 52 Week Low
- ANNX $1.29
- CATX $1.60
- 52 Week High
- ANNX $7.85
- CATX $15.28
- Technical
- Relative Strength Index (RSI)
- ANNX 62.43
- CATX 42.92
- Support Level
- ANNX $2.32
- CATX $3.33
- Resistance Level
- ANNX $2.70
- CATX $3.74
- Average True Range (ATR)
- ANNX 0.16
- CATX 0.23
- MACD
- ANNX 0.06
- CATX 0.01
- Stochastic Oscillator
- ANNX 87.57
- CATX 12.31
About ANNX Annexon Inc.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.
About CATX Perspective Therapeutics Inc.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.